AVITA Medical, Inc. (RCEL) Common Equity (2018 - 2026)

AVITA Medical (RCEL) has reported Common Equity for 9 consecutive years, with -$27.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 115.93% year-over-year to -$27.8 million; the trailing twelve-month figure through Jun 2026 stood at -$27.8 million (down 115.93% YoY), and the FY2025 full-year result was -$16.6 million, down 470.08% from the prior year.
• Common Equity slipped to -$27.8 million in Q2 2026 per RCEL's latest filing, from -$16.6 million in the prior quarter.
• Across five years, Common Equity topped out at $97.8 million in Q1 2022 and bottomed at -$27.8 million in Q2 2026.
• Historically, Common Equity has averaged $36.8 million across 5 years, with a median of $32.6 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Common Equity decreased 17.76% in 2022, then slumped 470.08% in 2025.
• Over 5 years, Common Equity stood at $84.7 million in 2022, then sank by 42.11% to $49.1 million in 2023, then plunged by 90.83% to $4.5 million in 2024, then plunged by 470.08% to -$16.6 million in 2025, then tumbled by 67.2% to -$27.8 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$27.8 million, -$16.6 million, and -$6.7 million for Q2 2026, Q4 2025, and Q3 2025 respectively.